What is the official website of Roche Polska ?

The official website of Roche Polska is http://www.roche.pl.

What is Roche Polska's cybersecurity risk score?

Roche Polska has an AI-generated cybersecurity risk score of 749 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has Roche Polska experienced?

According to Rankiteo, Roche Polska currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Roche Polska been affected by any supply chain cyber incidents ?

According to Rankiteo, Roche Polska has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Roche Polska have SOC 2 Type 1 certification ?

According to Rankiteo, Roche Polska is not certified under SOC 2 Type 1.

Does Roche Polska have SOC 2 Type 2 certification ?

According to Rankiteo, Roche Polska does not hold a SOC 2 Type 2 certification.

Does Roche Polska comply with GDPR ?

According to Rankiteo, Roche Polska is not listed as GDPR compliant.

Does Roche Polska have PCI DSS certification ?

According to Rankiteo, Roche Polska does not currently maintain PCI DSS compliance.

Does Roche Polska comply with HIPAA ?

According to Rankiteo, Roche Polska is not compliant with HIPAA regulations.

Does Roche Polska have ISO 27001 certification ?

According to Rankiteo,Roche Polska is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Roche Polska operate in ?

Roche Polska operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Roche Polska have ?

Roche Polska employs approximately 1 people worldwide.

Does Roche Polska own any subsidiaries ?

Roche Polska presently has no subsidiaries across any sectors.

How many LinkedIn followers does Roche Polska have ?

Roche Polska's official LinkedIn profile has approximately 28,873 followers.

What is the NAICS classification code for Roche Polska ?

Roche Polska is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Roche Polska have a Crunchbase profile ?

No, Roche Polska does not have a profile on Crunchbase.

Does Roche Polska have a LinkedIn profile ?

Yes, Roche Polska maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/rochepolska.

How many cybersecurity incidents has Roche Polska experienced ?

As of October 21, 2026, Rankiteo reports that Roche Polska has not experienced any cybersecurity incidents.

How many peer or competitor companies does Roche Polska have ?

Roche Polska has an estimated 5,778 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Roche Polska

Boost Score +25 with badge (5 left)

749

/1000

Moderate

774

/1000

Fair

Roche Polska Vendor Cyber Rating & Cyber Score

roche.pl

Add Your Compliance Badge

Roche Polska jest liderem wśród firm zajmujących się dostarczaniem innowacyjnych rozwiązań w zakresie ochrony zdrowia. Od ponad 100 lat wspomagamy polskich lekarzy w ich codziennej walce o zdrowie i życie pacjentów, współpracujemy również ze środowiskami akademickimi i medycznymi. Globalna strategia Roche koncentruje się na diagnostyce molekularnej oraz terapiach celowanych. Posiadamy nowoczesne i unikalne portfolio w takich dziedzinach terapeutycznych jak: onkologia, nefrologia, transplantologia, reumatologia, neurologia, kardiologia i choroby zakaźne. Jesteśmy liderem w obszarze medycyny personalizowanej – strategii leczenia, która polega na dopasowaniu optymalnej terapii dla każdego pacjenta. W Polsce działają światowej klasy ośrodki

Roche Polska

Roche Polska CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Roche Polska Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Roche Polska

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Roche Polska in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Roche Polska in 2026.

Incident Types Roche Polska vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Roche Polska in 2026.

Incident History - Roche Polska (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Roche Polska Subsidiaries

Roche Polska

Pharmaceutical Manufacturing

Website: http://www.roche.pl

Company Size: 501-1,000 employees

RocheBiotechnology Research

Roche Diagnostics USABiotechnology Research

Roche MéxicoPharmaceutical Manufacturing

Roche DeutschlandBiotechnologieforschung

GenentechBiotechnology Research

Genentech MedicalBiotechnology Research

Loading…

Roche Polska Similar Companies

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Loading…

NEWS

Roche Polska CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

September 04, 2025 07:00 AM

We Support Cybersecurity

'We have succeeded in transforming the .pl domain from being among the most dangerous, with the highest number of scam websites,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-113705

SUMMARY

A vulnerability was determined in a2aproject a2a-rs up to 0.4.3. This issue affects some unknown processing of the file a2a-server/src/error.rs. Executing a manipulation can lead to information exposure through error message. The attack can be executed remotely. This patch is called 713b943af94ab2d521d483b841618b97a2e78a4d. A patch should be applied to remediate this issue.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:N/A:N

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-9825

SUMMARY

IBM Cyber Fraud 1.0.0 through 1.0.2 has a missing secure attribute allowing sensitive cookies to be transmitted over unencrypted connections, potentially enabling an attacker to intercept session data through network-based attacks.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

https://www.ibm.com/support/pages/node/7290671

CVE-2026-94402

SUMMARY

IBM Carbon Charts 0.4.0 through 1.27.19 is vulnerable to cross-site scripting. The MeterChart component's Title.truncateTitle() function re-inserts a substring of user-supplied label text into the DOM via an unsanitized innerHTML write when the title exceeds the available container width. A remote attacker could exploit this vulnerability to execute arbitrary JavaScript in the victim's browser session.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Impact Score

2.7

Exploitability

2.8

REFERENCES

https://www.ibm.com/support/pages/node/7291785

CVE-2026-93888

SUMMARY

IBM Sterling Connect Direct for Unix 6.4.0.0 through 6.4.0.6 and 6.3.0.0 through 6.3.0.7 apnotify utility is vulnerable to a code injection due to insufficient validation of user input.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.ibm.com/support/pages/node/7292127

CVE-2026-93744

SUMMARY

IBM i 7.3, 7.4, 7.5, and 7.6 could allow an unathenticated remote attacker to bypass security restrictions due to improper access control. By sending a specially crafted HTTP request to any URL within the Navigator application prior to authentication, a bad actor could exploit this vulnerability to alter server-side session security state.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

3.9

REFERENCES

https://www.ibm.com/support/pages/node/7292223

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Roche Polska Vendor Cyber Rating & Cyber Score

Roche Polska A.I CyberSecurity Scoring

Roche Polska CyberSecurity News & History

Roche Polska Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Roche Polska

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Roche Polska vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Roche Polska (X = Date, Y = Severity)

Roche Polska Subsidiaries

Roche Polska

Roche Polska Similar Companies

Novartis

Glenmark Pharmaceuticals

UCB

Lonza

Alkem Laboratories Ltd.

Cipla

Johnson & Johnson Innovative Medicine

MENARINI Group

Zoetis

Roche Polska CyberSecurity News

We Support Cybersecurity

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Roche Polska CyberSecurity News & History

Roche Polska Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Roche Polska

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Roche Polska vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Roche Polska (X = Date, Y = Severity)

Roche Polska Subsidiaries

Roche Polska

Roche Polska Similar Companies

Novartis

Glenmark Pharmaceuticals

UCB

Lonza

Alkem Laboratories Ltd.

Cipla

Johnson & Johnson Innovative Medicine

MENARINI Group

Zoetis

Roche Polska CyberSecurity News

We Support Cybersecurity

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo